Koninklijke Philips (NYSE:PHG) Announces Quarterly Earnings Results, Beats Expectations By $0.12 EPS

Key Points

• Koninklijke Philips reported a quarterly earnings per share (EPS) of $0.41, exceeding analyst expectations by $0.12.
• The stock has a market capitalization of $27.29 billion and an average analyst rating of "Buy", with some upgrades from analysts recently.
• Institutional investments have notably increased, with firms like AQR Capital Management raising their stakes by over 60% in the first quarter.

Koninklijke Philips (NYSE:PHG - Get Free Report) issued its quarterly earnings results on Tuesday. The technology company reported $0.41 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.29 by $0.12, Zacks reports. Koninklijke Philips had a net margin of 1.00% and a return on equity of 11.95%. The company had revenue of $5.05 billion during the quarter, compared to the consensus estimate of $4.35 billion.

Koninklijke Philips Stock Up 1.0%

Koninklijke Philips stock traded up $0.26 during trading on Friday, reaching $26.46. The stock had a trading volume of 1,781,655 shares, compared to its average volume of 1,215,315. The stock has a market cap of $25.48 billion, a PE ratio of 139.26, a P/E/G ratio of 0.72 and a beta of 0.76. The company has a quick ratio of 0.79, a current ratio of 1.26 and a debt-to-equity ratio of 0.69. Koninklijke Philips has a 52-week low of $21.48 and a 52-week high of $32.91. The business has a 50 day moving average price of $24.03 and a 200 day moving average price of $24.98.

Institutional Trading of Koninklijke Philips

Institutional investors have recently modified their holdings of the stock. AQR Capital Management LLC lifted its position in shares of Koninklijke Philips by 60.8% during the 1st quarter. AQR Capital Management LLC now owns 17,010 shares of the technology company's stock worth $432,000 after buying an additional 6,429 shares during the last quarter. Jane Street Group LLC lifted its position in shares of Koninklijke Philips by 125.8% during the 1st quarter. Jane Street Group LLC now owns 104,024 shares of the technology company's stock worth $2,642,000 after buying an additional 57,952 shares during the last quarter. Royal Bank of Canada lifted its position in shares of Koninklijke Philips by 1.3% during the 1st quarter. Royal Bank of Canada now owns 269,829 shares of the technology company's stock worth $6,854,000 after buying an additional 3,540 shares during the last quarter. Finally, Goldman Sachs Group Inc. lifted its position in shares of Koninklijke Philips by 1.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 846,253 shares of the technology company's stock worth $21,495,000 after buying an additional 12,908 shares during the last quarter. Hedge funds and other institutional investors own 13.67% of the company's stock.

Analyst Ratings Changes

Separately, Wall Street Zen downgraded shares of Koninklijke Philips from a "buy" rating to a "hold" rating in a research note on Saturday. Two equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy".

Koninklijke Philips Company Profile

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.